Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Plus Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04561206Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Nov 2021
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin and nivolumab in classical Hodgkin lymphoma (cHL), sponsored by City of Hope. Primary endpoint: Progression-Free Survival at 24 months. Started Nov 2021; status: recruiting.
02
Drugs
brentuximab vedotinnivolumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04561206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561206.